Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,995 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.
Saka H, Kitagawa C, Kogure Y, Takahashi Y, Fujikawa K, Sagawa T, Iwasa S, Takahashi N, Fukao T, Tchinou C, Landers D, Yamada Y. Saka H, et al. Among authors: takahashi n, takahashi y. Invest New Drugs. 2017 Aug;35(4):451-462. doi: 10.1007/s10637-016-0416-x. Epub 2017 Jan 10. Invest New Drugs. 2017. PMID: 28070720 Free PMC article. Clinical Trial.
Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Takahashi N, Yamada Y, Taniguchi H, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y. Takahashi N, et al. Arch Med Res. 2014 Jul;45(5):366-74. doi: 10.1016/j.arcmed.2014.05.004. Epub 2014 May 13. Arch Med Res. 2014. PMID: 24830936
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Shirakawa T, Kato K, Nagashima K, Nishikawa A, Sawada R, Takahashi N, Shoji H, Sasaki Y, Honma Y, Iwasa S, Takashima A, Okita N, Hamaguchi T, Yamada Y, Shimada Y. Shirakawa T, et al. Among authors: takahashi n. Cancer Chemother Pharmacol. 2014 Dec;74(6):1207-15. doi: 10.1007/s00280-014-2597-3. Epub 2014 Sep 30. Cancer Chemother Pharmacol. 2014. PMID: 25267597
DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.
Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H, Ishioka C. Ouchi K, et al. Among authors: takahashi m, takahashi n, takahashi h, takahashi s. Cancer Sci. 2015 Dec;106(12):1722-9. doi: 10.1111/cas.12827. Epub 2015 Nov 12. Cancer Sci. 2015. PMID: 26426205 Free PMC article.
Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
Takahashi N, Furuta K, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y, Yamada Y. Takahashi N, et al. Oncotarget. 2016 Jan 26;7(4):4925-38. doi: 10.18632/oncotarget.6753. Oncotarget. 2016. PMID: 26716644 Free PMC article.
Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
Sasaki Y, Hamaguchi T, Yamada Y, Takahashi N, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Nagai Y, Taniguchi H, Boku N, Ushijima T, Shimada Y. Sasaki Y, et al. Among authors: takahashi n. Asian Pac J Cancer Prev. 2016;17(2):539-43. doi: 10.7314/apjcp.2016.17.2.539. Asian Pac J Cancer Prev. 2016. PMID: 26925640 Free article.
5,995 results